INFORMATION PAPER

DHA-IHD 14 Aug 2023

SUBJECT: Counting Doses in Combined Regimens of Monovalent and Bivalent Hepatitis A and Hepatitis B vaccines

- Purpose. To describe the required number of doses, using various combinations of the hepatitis vaccines: three antigen, monovalent (single antigen) hepatitis A and hepatitis B vaccines and the bivalent (combination hepatitis A and hepatitis B) vaccine, to ensure adequate immunity against both diseases.
- 2. Facts.
 - a. Service members and recruits may include personnel who are 17 years of age or older and must be screened by age to ensure they receive age-appropriate doses (pediatric/adolescent vs. adult) of hepatitis vaccines, depending on version of vaccine available. The age, at the date of the dose administration, determines the dosage of the vaccine to be administered that day.
 - b. Two monovalent hepatitis A vaccines are marketed in the United States: Havrix (manufactured by GlaxoSmithKline or GSK) and Vaqta (manufactured by Merck).
 - c. Three monovalent hepatitis B vaccines are marketed in the United States: Engerix-B (manufactured by GlaxoSmithKline), Heplisav-B (manufactured by Dynavax) and Recombivax-HB (manufactured by Merck).
 - d. One three antigen hepatitis B vaccine is marketed in the Unites States: PreHevbrio (manufactured by VBI Vaccines).
 - e. Single combination hepatitis A & B vaccine: GlaxoSmithKline markets Twinrix, a combination of their hepatitis A and hepatitis B vaccines.
 - f. The age-specific doses and dosing schedule of the hepatitis vaccines are as follows:

Subject: Counting Doses in Combined Regimens of Monovalent and Bivalent Hepatitis A and Hepatitis B vaccines

Age	Number of Doses	Vaccine Dosage and Schedule
18 years of age or younger	1 initial dose and 1 booster dose	Administer an initial dose of 0.5 mL and a booster dose of 0.5 mL between 6 to12 months later
19 years of age or older	1 initial dose and 1 booster dose	Administer an initial dose of 1 mL and a booster dose of 1 mL between 6 to 12 months later

Monovalent Hepatitis A Vaccine (HAVRIX (GSK) or VAQTA (Merck))

Monovalent Hepatitis B Vaccine (ENGERIX-B (GSK) or RECOMBIVAX• HB (Merck))

Age	Number of Doses	Vaccine Dosage and Schedule
19 years of age or younger	3 dose series	Administer an initial dose of 0.5 mL and then the next two doses of 0.5 mL at 1 month and 6 months from the initial dose
20 years of age or older	3 dose series	Administer an initial dose of 1 mL and then the next two doses of 1 mL at 1 month and 6 months from the initial dose

Bivalent Hepatitis B Vaccine (TWINRIX (GSK))

Age	Number of Doses	Vaccine Dosage and Schedule
18 years of age and older	3 dose series	Administer 1 mL at of 0, 1, 6 months

Three Antigen Hepatitis B Vaccine (PreHevbrio (VBI Vaccines))

Age	Number of Doses	Vaccine Dosage and Schedule
18 years of age and older	3 dose series	Administer 1 mL at of 0, 1, 6 months

Subject: Counting Doses in Combined Regimens of Monovalent and Bivalent Hepatitis A and Hepatitis B vaccines

Age	Number of Doses	Vaccine Dosage and Schedule
18 years of age and older	2 dose series	Administer an initial dose of 0.5 mL and then the final dose of 0.5 mL at 1 month.

Monovalent Hepatitis B Vaccine (HEPLISAV-B (Dynavax))

NOTE: A single dose of HEPLISAV-B can serve as a valid dose of hepatitis B vaccine for the 3- dose ENGERIX-B or RECOMBIVAX-HB or PreHevbio series if age criteria are met.

g. Age-specific doses (adult vs. pediatric/adolescent) must also be administered when the vaccine schedule includes both the monovalent and bivalent hepatitis vaccines. The mixed regimen of vaccines that induce adequate immunity against hepatitis A and hepatitis B are shown below. The individual vaccines within the combinations below can be administered in any sequence if proper minimum timing between doses is observed. When Twinrix is part of the regimen, maintain the dose spacing requirement for Twinrix.

Hepatitis A and B (TWINRIX)	Hepatitis A (HAVRIX or VAQTA)	Hepatitis B (ENGERIX- B, HEPLISAV-B or RECOMBIVAX-HB) or PreHevbrio		
	17 years of age			
	2 doses HepA (0.5 mL)	3 doses ENGERIX-B or RECOMBIVAX-HB (0.5 mL); 0 HEPLISAV-B; 0 PreHevbrio		
	18 years of age			
	2 doses HepA (0.5 mL)	3 doses ENGERIX-B or RECOMBIVAX-HB (0.5 mL) or PreHevbrio (1 mL) or 2 doses HEPLISAV-B (0.5 mL)		
1 dose Twinrix (1 mL)	2 doses HepA (0.5 mL) separated by 5 months	2 doses ENGERIX-B or RECOMBIVAX-HB or HEPLISAV-B (0.5 mL) or PreHevbrio (1 mL)		

Mixed Regimen of Vaccines to Complete Hepatitis A and B Series

Subject: Counting Doses in Combined Regimens of Monovalent and Bivalent Hepatitis A and Hepatitis B vaccines

2 doses Twinrix (1 ml)	1 dose HepA (0.5 mL) administered 5 months after 2nd dose of Twinrix	1 dose ENGERIX-B or RECOMBIVAX-HB or HEPLISAV-B (0.5 mL) or PreHevbrio (1 mL) administered 5 months after 2nd dose of Twinrix
	19 years of age	
		3 doses ENGERIX-B or RECOMBIVAX-HB (0.5 mL) or PreHevbrio (1mL); or 2 doses HEPLISAV-B (0.5 mL)
1 dose Twinrix (1 mL)		2 doses ENGERIX-B, RECOMBIVAX-HB(0.5 mL),or HEPLISAV-B (0.5 mL), or PreHevbrio (1 mL)
2 doses Twinrix (1 ml)		1 dose ENGERIX-B or RECOMBIVAX-HB or HEPLISAV-B (0.5 mL) or PreHevbrio (1 mL) administered 5 months after 2nd dose of Twinrix

Hepatitis A and B (TWINRIX)	Hepatitis A (HAVRIX or VAQTA)	Hepatitis B (ENGERIX- B, HEPLISAV-B or RECOMBIVAX-HB or PreHevbrio)
	20 years of age and older	
	2 doses HepA (1 mL)	3 doses ENGERIX-B or RECOMBIVAX-HB or PreHevbrio (1.0 mL) or 2 doses HEPLISAV-B (0.5 mL)
1 dose Twinrix (1 ml)	2 doses HepA (1 mL) separated by 5 months	2 doses ENGERIX-B or RECOMBIVAX-HB or PreHevbrio (1 mL) or HEPLISAV-B (0.5 mL)
2 doses Twinrix (1 ml)	1 dose HepA (1 mL) administered 5 months after 2nd dose of Twinrix	1 dose ENGERIX-B or RECOMBIVAX-HB or PreHevbrio (1.0 mL) or HEPLISAV-B (0.5 mL) administered 5 months after 2nd dose of Twinrix

Subject: Counting Doses in Combined Regimens of Monovalent and Bivalent Hepatitis A and Hepatitis B vaccines

Note: There are approved variations of recommendations based on the package inserts for the available vaccines.

- 3. References.
 - a. Immunization Action Coalition, Ask the Experts, Hepatitis A on 8 AUG 2023. <u>http://www.immunize.org/catg.d/p2081.pdf</u> and <u>https://www.immunize.org/askexperts/experts_hepa.asp</u>
 - b. The ABCs of Hepatitis. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. <u>https://www.cdc.gov/hepatitis/resources/professionals/pdfs/abctable.pdf</u>
 - c. Epidemiology and Prevention of Vaccine-Preventable Diseases, ThePink Book: Course Textbook - 14th Edition (2021). <u>https://www.cdc.gov/vaccines/pubs/pinkbook/hepb.html</u>
 - Weng, Mark et al. "Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022." MMWR. Morbidity and Mortality Weekly Report vol. 71,13 477-483. 1 Apr. 2022. <u>https://www.cdc.gov/mmwr/volumes/71/wr/pdfs/mm7113a1-H.pdf</u>

Central Region Vaccine Safety Hub Approved: Deputy Chief, Immunization Healthcare Division 877-438-8222 (DSN 761-4245), option 1